Deferasirox
Product Images NDC 45963-455

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Deferasirox (NDC 45963-455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

9c6b4e1d-figure-01 (Image 1)

Chemical structure diagram of the active ingredient Deferasirox. The diagram shows the molecular arrangement with key atoms and bonds depicted, consistent with a chemical structural formula representation.*

FDA Label Image

250 (Image 10)

Deferasirox Tablets for Oral Suspension 250 mg label by Actavis Pharma, Inc. The label states 30 tablets per bottle and includes instructions not to chew or swallow whole, with tablets to be dispersed in water, orange, or apple juice before ingestion. It provides storage information and cautions to keep out of reach of children. The label also references a package insert for detailed dosing information and a website for medication guides.*

FDA Label Image

500 (Image 11)

Label for Deferasirox Tablets for Oral Suspension 500 mg by Actavis Pharma, Inc., manufactured for Teva Pharmaceuticals. The carton contains 30 tablets with instructions to dispense medication guides and store at controlled room temperature. The label includes usage warnings, barcode, and serialization coding area.*

FDA Label Image

9c6b4e1d-figure-02 (Image 2)

Chemical structure diagram of Deferasirox, showing the molecular framework and atomic connections of the active ingredient supplied by Actavis Pharma, Inc.*

FDA Label Image

9c6b4e1d-figure-03 (Image 3)

Chemical structure of Deferasirox, shown as a molecular diagram with connected atoms and bonds arranged in a distinctive pattern.*

FDA Label Image

9c6b4e1d-figure-04 (Image 4)

Chemical structure of deferasirox, showing its molecular framework with three hydroxyl groups and aromatic rings connected through nitrogen-containing linkages.*

FDA Label Image

9c6b4e1d-figure-05 (Image 5)

A bar chart illustrating the change in liver iron content (mg Fe/g dry weight) and serum ferritin (mcg/L) in relation to different doses of Deferasirox tablets (mg/kg/day). The chart shows data for doses 5, 10, 20, and 30 mg/kg/day with sample sizes noted, comparing liver iron content and serum ferritin changes after treatment.*

FDA Label Image

9c6b4e1d-figure-06 (Image 6)

Chemical structure diagram of Deferasirox showing its molecular arrangement with rings and various bonds, consistent with drug product data from Actavis Pharma, Inc.*

FDA Label Image

9c6b4e1d-figure-07 (Image 7)

Chemical structure of deferasirox, showing its molecular framework including rings and functional groups as depicted in the image.*

FDA Label Image

9c6b4e1d-figure-08 (Image 8)

Chemical structure diagram of Deferasirox showing its molecular framework, including rings and atomic connections as part of the active pharmaceutical ingredient's depiction.*

FDA Label Image

125 (Image 9)

Label for Deferasirox Tablets for Oral Suspension, 125 mg, manufactured for Teva Pharmaceuticals by Actavis Pharma, Inc. The label indicates a package size of 30 tablets, with instructions to not chew or swallow whole and to dispense tablets in water, orange, or apple juice prior to ingestion. Storage and dosage details, barcode, and a serialization coding area are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.